| Bioactivity | Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy[1][2][3]. |
| Target | SV2A |
| Invitro | Seletracetam lithium decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A[2].Seletracetam lithium decreases synaptic responses in a time-, frequency- and concentration-dependent manner[2].Seletracetam lithium modifies rates of presynaptic release[2].Seletracetam lithium inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro[3]. |
| Name | Seletracetam lithium |
| Formula | C10H14F2LiN2O2 |
| Molar Mass | 239.17 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pollard JR, et al. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008 Jan;9(1):101-7. [2]. Martella G, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009 Apr;50(4):702-10. [3]. Yang X, et al. Seletracetam enhances short term depression in vitro. Epilepsy Res. 2015 Nov;117:17-22. |
Seletracetam lithium
CAS: F: C10H14F2LiN2O2 W: 239.17
Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the res
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.